BioAtla (BCAB) Stock Overview
A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BCAB Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioAtla, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$1.43 |
| 52 Week Low | US$0.14 |
| Beta | 1.06 |
| 1 Month Change | -46.56% |
| 3 Month Change | -79.15% |
| 1 Year Change | -62.22% |
| 3 Year Change | -95.40% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation
Jul 21
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
Promising results in clinical programs and strategic partnerships indicate potential for increased revenue, improved net margins, and financial stability through collaboration income.BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 02Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Shareholder Returns
| BCAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.4% | 1.3% | 0.5% |
| 1Y | -62.2% | 25.7% | 10.7% |
Return vs Industry: BCAB underperformed the US Biotechs industry which returned 29% over the past year.
Return vs Market: BCAB underperformed the US Market which returned 13.2% over the past year.
Price Volatility
| BCAB volatility | |
|---|---|
| BCAB Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCAB's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 61 | Jay Short | www.bioatla.com |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.
BioAtla, Inc. Fundamentals Summary
| BCAB fundamental statistics | |
|---|---|
| Market cap | US$13.70m |
| Earnings (TTM) | -US$64.71m |
| Revenue (TTM) | n/a |
Is BCAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$46.73m |
| Gross Profit | -US$46.73m |
| Other Expenses | US$17.98m |
| Earnings | -US$64.71m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 04:33 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioAtla, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |